Daiichi pulls out of India with closure of 170-strong R&D plant

pharmafile | January 11, 2017 | News story | Manufacturing and Production, Research and Development Daiichi Sankyo, Ranbaxy, Sun Pharma 

Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in its global restructuring programme in the hopes of “decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.”

The decision comes only a year after the company announced the closure of an antibody production plant in Germany and a UK facility as part of this global plan.

The facility employs 170 staff engaged in drug discovery research, though it is currently unclear how they will be affected by the move. All R&D function will be transferred to the company’s Japanese division, effectively ending Daiichi’s presence in India.

The company originally acquired the facility as part of its takeover of India’s largest generic drugs manufacturer Ranbaxy in 2008, but after some troubling years and import bans and misconduct charges from the FDA, Daiichi was forced to sell the ailing firm to Sun Pharmaceuticals for $4 billion in 2014.

Matt Fellows

Related Content

Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment

Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination …

AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC

AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the …

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …

Latest content